UNCY

Unicycive is a clinical-stage biotech with no product revenue and no near-term path to it: the last reported product sales were $675K in FY2023, and FY2024/FY2025 show none. The company states plainly it 'expect[s] to continue to operate at a net loss for at least the next several years,' has an accumulated deficit of $127.8M, and burned $31.3M of operating cash in FY2025. Against that burn it holds $29.2M of cash — roughly one year of runway. The MD&A confirms operating expenses will 'increase significantly' as it advances OLC and UNI-494, so the funding gap is a matter of when, not if. On these facts the trailing P/S of 214x is meaningless; the equity is a call option on two kidney assets, not a valued operating business.

The capital story is the whole story, and it is dilutive. The 10-K discloses a $50M Series B convertible preferred (conversion price $1.00, far below the $5.73 price) and a $100M ATM with Guggenheim that lets the company sell common stock 'from time to time' — a standing overhang that caps upside and prints new shares into any rally. Share count already fell 78.9% YoY to 25.2M, the signature of a reverse split done to maintain listing, which is a red flag on prior dilution, not a sign of health. Stockholders' equity of $30.2M is essentially the cash balance; liabilities/equity of 0.63x looks benign only because there is little tangible business to lever.